Company Overview
TriSalus Life Sciences, Inc. is dedicated to the research, development, and commercialization of a drug delivery technology platform alongside immuno-oncology therapeutics specifically designed to enhance patient outcomes for those suffering from difficult-to-treat liver and pancreatic cancers within the United States. The company operates within the Healthcare sector and the Medical Devices industry, positioning it as a specialized entity focused on oncology solutions rather than general healthcare services. Its operational scale is defined by a market capitalization of $245.84M, an annual revenue of $45.15M, and an employee base of 102 individuals. These figures indicate that TriSalus Life Sciences, Inc. functions as a mid-sized enterprise within the biotechnology space, where a market cap under $250M and revenue under $50M typically suggest a company in a growth or development phase that has yet to achieve sustained profitability at scale. The relatively small workforce of 102 employees relative to its revenue suggests a high-intensity operational model common in R&D-driven sectors, where capital and specialized talent are concentrated on specific therapeutic targets rather than broad distribution networks.
Financial Health
The company reported revenue of $45.15M over the trailing twelve months, yet this generated a net income of -$69,690,000 and an EBITDA of -$26,320,000, revealing a significant gap between top-line growth and bottom-line profitability. This disparity indicates a cost structure where expenses, likely driven by research and development activities and regulatory costs associated with immuno-oncology therapeutics, substantially outpace the gross margins generated by sales. Free cash flow stands at -$8,759,250, which signifies that the company is burning cash to fund its operations and growth initiatives, thereby limiting its immediate financial flexibility and reliance on external capital sources. Operating leverage has not yet been achieved, as evidenced by a gross margin of 84.6%, which is robust for a medical device company, but an operating margin of -24.8% and a profit margin of -86.9% demonstrate that overhead and R&D costs are consuming the majority of gross profits. The balance sheet shows cash reserves of $20.44M against total debt of $34.44M, while the debt-to-equity ratio is listed as N/A due to the company's negative equity position. This capital structure implies a leveraged stance where the company must generate sufficient operating income to cover its debt obligations and avoid further dilution. Liquidity is supported by a current ratio of 2.80, indicating that the company holds sufficient current assets to cover its short-term liabilities nearly three times over. Return on Equity is N/A due to negative shareholders' equity, and Return on Assets is -56.8%, which reveals that management's effectiveness in generating returns from its asset base is currently negative, a typical characteristic of pre-revenue or early-stage clinical development companies.
Valuation Assessment
Valuation multiples for TriSalus Life Sciences, Inc. reflect its unprofitable status, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -16.04, implying that the market expects earnings to turn positive in the future to justify a positive multiple. The Price to Book ratio is -5.92, indicating that the company's market value is significantly below its book value, a metric often seen in entities with intangible assets like intellectual property that are not fully captured on the balance sheet. Alternative valuation metrics provide further insight, with a Price to Sales ratio of 5.44 and an EV/EBITDA of -9.87, suggesting that investors are pricing the stock based on potential future growth rather than current earnings or book value. The stock's price volatility is contained within a 52-week range of $3.42 to $7.95, meaning the current trading price sits between these extremes, though the exact current price percentage relative to the high or low requires the specific current share price which is not provided in the available facts. The Beta is 0.44, which indicates that the stock exhibits low volatility relative to the broader market, moving less than half as much as the market index during periods of fluctuation. This lower beta suggests the stock may serve as a diversifier in a portfolio, though the negative valuation multiples caution against interpreting the price as a direct reflection of current earnings power.
Growth & Income
Revenue growth for the trailing twelve months stands at 59.8%, while Earnings Growth (YoY) is N/A due to the company's reported net losses. Since earnings are negative, they are not growing faster than revenue; rather, the company is expanding its top line while simultaneously deepening its losses, which implies a high burn rate required to achieve future profitability. The company does not pay dividends, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning it reinvests all available cash flow into research, development, and commercialization efforts rather than returning capital to shareholders. Consequently, the overall growth and income profile is characterized by rapid revenue expansion coupled with a lack of current income generation, relying entirely on the eventual success of its drug delivery platform and immuno-oncology therapeutics to transition from a loss-making entity to a profitable one.